优化基因表达谱在早期乳腺癌中的应用
研究回顾性分析五家机构2006至2013年1113例激素受体阳性、淋巴结阴性乳腺癌患者的Oncotype DX复发评分与病理报告,利用局部检测的免疫组化标志物建立预测复发评分风险类别的模型。模型在1113例中超过55%的病例以超过95%的置信度仅凭组织病理学标志物确定风险类别,在472例独立验证集中正确预测风险类别52.5%。作者认为将组织病理学与分子信息整合到决策过程可使分子工具聚焦于风险不确定的病例。
要点
- 组织病理学标志物单独在超过55%的病例中以超过95%置信度确定复发评分风险类别。
- 验证集中模型正确预测风险类别52.5%(248/472)。
- 整合决策模型不改变总体检测频率,但可减少临床高风险和低风险病例的检测、增加临床中间风险病例的检测。
核心结论
- 所提出的模型在多数病例中准确预测高风险和低风险复发评分类别(>25或≤25)。
- 将组织病理学与分子信息整合到决策过程,可使新分子工具的使用重新聚焦于风险不确定的病例。
研究设计与样本
- 回顾性审查五家机构2006年至2013年间开具的Oncotype DX复发评分与病理报告(n=1113)。
- 使用局部检测的病理标志物(雌激素受体、孕激素受体、Ki-67、人表皮生长因子受体2和Elston分级)建立预测基于复发评分的风险类别的模型。
- 在一个中心评估整合临床治疗指南、免疫组化标志物和Oncotype DX的整合决策模型下的检测开具模式。
- 最终锁定模型在独立样本中测试(n=472)。
主要发现
- 复发评分分布在各机构间相似,与已报告的临床实践经验相似,且随时间保持稳定。
- 组织病理学标志物单独在超过55%(616/1113)的病例中以超过95%的置信度确定风险类别。
- 将整合决策模型应用于一个中心显示,检测频率总体上不会改变,但检测开具模式会大幅改变,对估计临床高风险或临床低风险病例的检测减少,对临床中间风险病例的检测增加。
- 在验证集中,模型正确预测风险类别52.5%(248/472)。
关键数值与推荐
- 模型预测高风险和低风险复发评分类别(>25或≤25)。
- 组织病理学标志物单独在超过55%(616/1113)的病例中以超过95%的置信度确定风险类别。
- 验证集中模型正确预测风险类别52.5%(248/472)。
临床怎么用
- 作者认为将组织病理学与分子信息整合到决策过程可使新分子工具的使用重新聚焦于风险不确定的病例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-positive, lymph node-negative breast cancer. We hypothesized that the clinical value of these new tools would be more fully realized when appropriately integrated with high-quality clinicopathologic data. Hence, we developed a model that uses routine pathologic parameters to estimate Oncotype DX recurrence score (ODX RS) and independently tested its ability to predict ODX RS in clinical samples. Patients and Methods We retrospectively reviewed ordered ODX RS and pathology reports from five institutions (n = 1,113) between 2006 and 2013. We used locally performed histopathologic markers (estrogen receptor, progesterone receptor, Ki-67, human epidermal growth factor receptor 2, and Elston grade) to develop models that predict RS-based risk categories. Ordering patterns at one site were evaluated under an integrated decision-making model incorporating clinical treatment guidelines, immunohistochemistry markers, and ODX. Final locked models were independently tested (n = 472). Results Distribution of RS was similar across sites and to reported clinical practice experience and stable over time. Histopathologic markers alone determined risk category with > 95% confidence in > 55% (616 of 1,113) of cases. Application of the integrated decision model to one site indicated that the frequency of testing would not have changed overall, although ordering patterns would have changed substantially with less testing of estimated clinical risk-high or clinical risk-low cases and more testing of clinical risk-intermediate cases. In the validation set, the model correctly predicted risk category in 52.5% (248 of 472). Conclusion The proposed model accurately predicts high- and low-risk RS categories (> 25 or ≤ 25) in a majority of cases. Integrating histopathologic and molecular information into the decision-making process allows refocusing the use of new molecular tools to cases with uncertain risk.
引用
- Kim HS, Umbricht CB, Illei PB, et al. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. J Clin Oncol. 2016. PMID: 27998227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。